EU Still Resisting COVID-19 Vaccine IP Waiver
EFPIA 'Deeply Concerned' About Compulsory Licensing Proposal
Executive Summary
The pharmaceutical industry and Médecins Sans Frontières have both criticized the EU’s proposals for avoiding a waiver of intellectual property rights on COVID-19 vaccines and treatments, albeit for different reasons.
You may also be interested in...
EU Ups The Ante On Opposition To COVID-19 IP Waiver
Leaked documents show that the European Commission has prepared a new proposal on compulsory licensing of coronavirus products to be tabled at the World Trade Organization’s Ministerial Conference next month.
Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination
Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.
More Pressure On COVID-19 Product Protections As Euro Parliament Backs IP Waiver
Expectations will be high after the COVID-19 product IP waiver plan took a big step forward and G7 leaders prepare for discussions on the global recovery from coronavirus, tackling climate change and other weighty subjects.